PDS Biotechnology Corp cotiza a 1.60 USD y tiene una capitalización bursátil de $116M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vul…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.13 | $-0.14 |
| Estimado | $-0.11 | $-0.13 | $-0.14 | $-0.20 |
| Sorpresa | — | — | +7.1% | +30.0% |
| Métrica | PDSB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -372.9% | -40.4% | -332.5% |
| ROA | -113.1% | -32.0% | -81.1% |
| Current Ratio | 2.98 | 2.84 | +0.14 |
| Debt / Equity | — | 0.28 | — |